Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10047498HBVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS10047499HBVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS10047500HBVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS10042433HBVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30016562HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30004960HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30082795HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30068158HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30068159HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TVIS30068160HIVENSG00000064393.16protein_codingHIPK2NoNo28996Q9H2X6
TCGA Plot Options
Drug Information
GeneHIPK2
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009447
UniProt IDQ9H2X6
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830